Nebula Research & Development LLC Sells 446 Shares of U.S. Physical Therapy, Inc. (NYSE:USPH)

Nebula Research & Development LLC lowered its stake in shares of U.S. Physical Therapy, Inc. (NYSE:USPH) by 4.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,333 shares of the company’s stock after selling 446 shares during the quarter. Nebula Research & Development LLC owned 0.06% of U.S. Physical Therapy worth $828,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. CBIZ Investment Advisory Services LLC grew its stake in shares of U.S. Physical Therapy by 59.8% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 326 shares of the company’s stock worth $29,000 after acquiring an additional 122 shares in the last quarter. Venturi Wealth Management LLC grew its position in U.S. Physical Therapy by 3,200.0% in the 4th quarter. Venturi Wealth Management LLC now owns 726 shares of the company’s stock worth $64,000 after purchasing an additional 704 shares in the last quarter. Pacer Advisors Inc. purchased a new stake in U.S. Physical Therapy in the 4th quarter valued at about $113,000. Mutual of America Capital Management LLC purchased a new stake in U.S. Physical Therapy in the 4th quarter valued at about $203,000. Finally, Dark Forest Capital Management LP bought a new position in shares of U.S. Physical Therapy during the 4th quarter worth approximately $247,000.

U.S. Physical Therapy Trading Up 1.6 %

Shares of U.S. Physical Therapy stock opened at $70.78 on Monday. The stock has a market capitalization of $1.08 billion, a P/E ratio of 75.30, a P/E/G ratio of 3.54 and a beta of 1.38. U.S. Physical Therapy, Inc. has a 52-week low of $62.77 and a 52-week high of $108.14. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.78 and a current ratio of 1.78. The stock’s 50-day simple moving average is $74.63 and its 200 day simple moving average is $84.47.

U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by ($0.04). The business had revenue of $180.45 million during the quarter, compared to the consensus estimate of $173.10 million. U.S. Physical Therapy had a net margin of 3.54% and a return on equity of 8.11%. As a group, research analysts anticipate that U.S. Physical Therapy, Inc. will post 2.67 EPS for the current year.

U.S. Physical Therapy Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 11th. Stockholders of record on Friday, March 14th were issued a $0.45 dividend. This is a positive change from U.S. Physical Therapy’s previous quarterly dividend of $0.44. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date was Friday, March 14th. U.S. Physical Therapy’s dividend payout ratio (DPR) is presently 97.83%.

Insider Activity

In other U.S. Physical Therapy news, COO Graham D. Reeve sold 1,730 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $82.11, for a total value of $142,050.30. Following the completion of the transaction, the chief operating officer now owns 7,168 shares in the company, valued at $588,564.48. This trade represents a 19.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. JMP Securities reaffirmed a “market outperform” rating and set a $113.00 price target on shares of U.S. Physical Therapy in a research report on Tuesday, April 22nd. JPMorgan Chase & Co. lowered their target price on U.S. Physical Therapy from $120.00 to $110.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 19th. Barrington Research cut their price target on shares of U.S. Physical Therapy from $108.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, February 28th. William Blair restated a “market perform” rating on shares of U.S. Physical Therapy in a report on Thursday, February 27th. Finally, StockNews.com cut shares of U.S. Physical Therapy from a “hold” rating to a “sell” rating in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $109.00.

U.S. Physical Therapy Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.